New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
07:40 EDTCBLICleveland BioLabs reports Q4 EPS (1c), consensus (12c)
Reports Q4 revenue $3.9M, consensus $1.74M.
News For CBLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 16, 2015
07:33 EDTCBLICleveland BioLabs announces completion of dosing in Phase 1 study of CBLB612
Cleveland BioLabs announced that a maximally tolerated dose has been reached and that dosing has been completed in a Phase 1 healthy subject study of CBLB612, an investigational drug in development for mobilization of hematopoietic stem cells, or HSCs, and for the prevention of chemotherapy-induced myelosuppression. The objectives of the study include establishing a maximally tolerated dose, evaluating the safety profile and pharmacokinetics of CBLB612, and characterizing the type, quantity and timing of HSC mobilization. Analysis of data from the 56 healthy volunteers enrolled in the study is ongoing and data are expected to be reported in Q2. This study is partially funded through a contract from the Ministry of Industry and Trade of the Russian Federation.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use